These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32812487)

  • 21. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
    Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
    Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relapse May Serve as a Mediator Variable in Longitudinal Outcomes in Multiple Sclerosis.
    Stone LA; Cutter GR; Fisher E; Richert N; McCartin J; Ohayon J; Bash C; McFarland H
    J Neuroimaging; 2016 May; 26(3):296-302. PubMed ID: 26686343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study.
    Kolčava J; Kočica J; Hulová M; Dušek L; Horáková M; Keřkovský M; Stulík J; Dostál M; Kuhn M; Vlčková E; Bednařík J; Benešová Y
    Mult Scler Relat Disord; 2020 Sep; 44():102262. PubMed ID: 32570179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of Gadolinium in Follow-Up MRI of Multiple Sclerosis Patients: Current Recommendations].
    Cruz A; Pereira D; Batista S
    Acta Med Port; 2024 Jan; 37(1):53-63. PubMed ID: 38183232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Central motor conduction time in progressive multiple sclerosis. Correlations with MRI and disease activity.
    Kidd D; Thompson PD; Day BL; Rothwell JC; Kendall BE; Thompson AJ; Marsden CD; McDonald WI
    Brain; 1998 Jun; 121 ( Pt 6)():1109-16. PubMed ID: 9648546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features.
    Tubridy N; Coles AJ; Molyneux P; Compston DA; Barkhof F; Thompson AJ; McDonald WI; Miller DH
    Brain; 1998 Feb; 121 ( Pt 2)():225-31. PubMed ID: 9549501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
    Cobo-Calvo A; Tur C; Otero-Romero S; Carbonell-Mirabent P; Ruiz M; Pappolla A; Villacieros Alvarez J; Vidal-Jordana A; Arrambide G; Castilló J; Galan I; Rodríguez Barranco M; Midaglia LS; Nos C; Rodriguez Acevedo B; Zabalza de Torres A; Mongay N; Rio J; Comabella M; Auger C; Sastre-Garriga J; Rovira A; Tintore M; Montalban X
    Neurology; 2023 Sep; 101(13):e1280-e1292. PubMed ID: 37468284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Childhood-onset multiple sclerosis with progressive dementia and pathological cortical demyelination.
    Bunyan RF; Popescu BF; Carter JL; Caselli RJ; Parisi JE; Lucchinetti CF
    Arch Neurol; 2011 Apr; 68(4):525-8. PubMed ID: 21482934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chronic inflammatory demyelinating polyradiculoneuropathy associated with central nervous system involvement--as compared to multiple sclerosis].
    Komori T; Ohtake T; Miyazaki Y; Hirose K; Tanabe H
    Rinsho Shinkeigaku; 1990 Sep; 30(9):939-43. PubMed ID: 2265502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo.
    Absinta M; Sati P; Masuzzo F; Nair G; Sethi V; Kolb H; Ohayon J; Wu T; Cortese ICM; Reich DS
    JAMA Neurol; 2019 Dec; 76(12):1474-1483. PubMed ID: 31403674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
    Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J
    Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis.
    Lebrun C; Cohen M; Mondot L; Ayrignac X; Labauge P
    Neurol Ther; 2017 Dec; 6(2):259-263. PubMed ID: 28840523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease.
    Siva A; Saip S; Altintas A; Jacob A; Keegan BM; Kantarci OH
    Mult Scler; 2009 Aug; 15(8):918-27. PubMed ID: 19667020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CNS demyelination with TNFα inhibitor exposure: A retrospective cohort study.
    Hutto SK; Rice DR; Mateen FJ
    J Neuroimmunol; 2021 Jul; 356():577587. PubMed ID: 33945946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of progression in primary progressive multiple sclerosis in a large Turkish cohort.
    Vural A; Derle E; Sayat-Gürel G; Karabudak R; Tuncer A
    Mult Scler Relat Disord; 2020 Feb; 38():101520. PubMed ID: 31743849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode.
    Tutuncu M; Demirci NO; Özer F; Saip S; Kantarci OH; Siva A
    Mult Scler; 2011 Oct; 17(10):1262-4. PubMed ID: 21135019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
    Balloy G; Pelletier J; Suchet L; Lebrun C; Cohen M; Vermersch P; Zephir H; Duhin E; Gout O; Deschamps R; Le Page E; Edan G; Labauge P; Carra-Dallieres C; Rumbach L; Berger E; Lejeune P; Devos P; N'Kendjuo JB; Coustans M; Auffray-Calvier E; Daumas-Duport B; Michel L; Lefrere F; Laplaud DA; Brosset C; Derkinderen P; de Seze J; Wiertlewski S;
    J Neurol; 2018 Oct; 265(10):2251-2259. PubMed ID: 30054790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Intravenous Cladribine in Patients with Rapidly Evolving or Early Secondary Progressive Multiple Sclerosis.
    Alshamrani F; Alnajashi H; Almuaigel MF
    Cureus; 2020 Feb; 12(2):e6995. PubMed ID: 32206459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma exchange for steroid-refractory relapses in multiple sclerosis: an observational, MRI pilot study.
    Meca-Lallana JE; Hernández-Clares R; León-Hernández A; Genovés Aleixandre A; Cacho Pérez M; Martín-Fernández JJ
    Clin Ther; 2013 Apr; 35(4):474-85. PubMed ID: 23541130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.